Industry Updates for the Psychedelics World

Psychedelics News

Industry

16 Nov 2022

Field Trip Announces New Ketamine Therapy Program: Freedom by Field Trip™

Field Trip Announces the Launch of Freedom by Field Trip™, a First-of-Its-Kind Ketamine Therapy Program...

By Microdose NewsDesk

Industry

15 Nov 2022

Clearmind Medicine Uplists to the NASDAQ

In surprising news, psychedelic upstart Clearmind Medicine has uplisted to the NASDAQ....

By Microdose NewsDesk

Industry

11 Nov 2022

Atai Reports Q3 Financials and Business Update

atai Life Sciences has the biggest product portfolio in the psychedelics medicine space, with over a dozen programs running under a wide range of subsidiary companies....

By Microdose NewsDesk

Industry

3 Nov 2022

PharmaTher Enters into Agreement to Commercialize Ketamine for Rett Syndrome

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

28 Oct 2022

Numinus Launches Ketamine Program for Chronic and Serious Illness

Numinus launches Ketamine for Chronic and Serious Medical Illness Program....

By Microdose NewsDesk

Industry

26 Oct 2022

Atai Completes Enrollment of Phase 2a Trial for Depression

atai’s subsidiary, has completed enrollment of Phase 2a double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine) for treatment-resistant depression....

By Microdose NewsDesk

Industry

25 Oct 2022

A Deeper Look at Atai Life Sciences’ R&D Day

Today, atai Life Sciences (Nasdaq: ATAI) held its much anticipated R&D Day, where management and scientific leaders walked investors through the company’s diverse medical pipeline....

By James Hallifax

Industry

24 Oct 2022

Top Reasons to be at Wonderland 2022 (Part 2)

Wonderland 2021 successfully established the event as the go-to industry gathering....

By Microdose

Industry

24 Oct 2022

Algernon Partners with Yale University for DMT Phase 2 Depression Trial

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study...

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result